Redefining microbial production
In today’s competitive biomanufacturing landscape, reducing production costs is critical.
Increasing recombinant protein and pDNA titres, along with improving protein solubility, can significantly lower the cost of manufacturing by maximising product yield per batch and minimising dependence on expensive downstream processing.
Developed and refined over more than a decade, our technology platform is designed to tackle these challenges and enable more efficient, scalable, and robust bioprocesses.
Proprietary technology platform
Our patented microbial technology provides our customers with a clear competitive advantage. By leveraging our proprietary platform, customers gain access to exclusive, high-performing microbial strains and optimised production processes that reduce development timelines, lower manufacturing costs, and minimise technical risk. This strong IP position not only supports faster scale-up and reliable production but also enhances our customers’ freedom to operate and strengthens their own intellectual property strategy, helping them bring innovative biologics and speciality molecules to market more efficiently and confidently.
Learn more about our technologies.
Publications
Growth-decoupled production
enGenes-eXpress technology enables the growth-decoupled production of biomolecules using E. coli, allowing for higher productivity, improved quality and reduced production costs. With its versatility, the technology can be used for the production of various biomolecules, including recombinant proteins, plasmid DNA, RNA, and small molecules, making it a valuable tool in bioprocessing. The phage-derived inhibitor peptide used in the technology is a breakthrough innovation that revolutionises the production of biomolecules, particularly in the pharmaceutical and biotech industries.
Extracellular secretion
The enGenes-eXtra technology enables the extracellular production of recombinant proteins by secretion, utilising the periplasmic space of E. coli and a leaky outer membrane to release the protein into the extracellular space. This approach allows for simplified purification processes and potentially higher yields of the desired protein. enGenes-eXtra technology is not only a novel and efficient way for extracellular production of recombinant proteins by secretion, but it also offers cost-effectiveness through reduced downstream processing needs, making it an attractive option for clients seeking high-quality protein production.
Genetic code expansion
The enGenes-eXpand technology for site-specific incorporation of non-canonical amino acids (NCAAs) has vast applications in fields like protein engineering, drug discovery, and biotechnology, by enabling the synthesis of modified proteins with tailored properties, as well as cost-effective incorporation of NCAAs into proteins for bioconjugation through click-chemistry.
Continuous manufacturing
enGenes-eXcite is a cutting-edge technology that enables the continuous manufacturing of biomolecules using E. coli, providing very high productivity at a very small footprint. With its high yield and scalability, enGenes-eXcite represents a promising solution for the cost-effective and sustainable production of biomolecules.
Plasmid DNA manufacturing
enGenes-eXcess technology is an efficient and robust platform for the manufacturing of high-quality plasmid DNA. Its upstream and downstream processes have been optimised to enable significant yield improvements and facilitate large-scale production of plasmid DNA for gene therapy and vaccine development. This technology allows for precise and reproducible production of high-quality plasmid DNA in a cost-effective manner.
Antibiotic-free manufacturing
The enGenes-eXchange technology offers a sustainable solution for antibiotic resistance marker-free recombinant protein production, using modified plasmids and E. coli strains that allow for antibiotic-free manufacturing of recombinant proteins and plasmid DNA. The technology offers a viable alternative to traditional methods that rely on the use of antibiotics, resulting in safer and more environmentally friendly production.
